$RLMD News
Last published 1w ago
- 1w agoRLMDRelmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in LondonGlobeNewswireCORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
- 1w agoRLMDRelmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026GlobeNewswireCORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
- 2mo agoRLMDRelmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewswireCORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
- 3mo agoRLMDRelmada Therapeutics, Inc. Second Quarter 2026 Earnings Call - RELMADA THERAPEUTICS INCEarnings Call TranscriptsThank you for watching. Thank you. Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Piano music Thank you
- 3mo agoRLMDRelmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireAdvancing NDV-01 toward IND filing expected by year-end 2026 with GMP manufacturing of clinical trial material underway. Initiation of the Phase 3 RESCUE registrational program upon IND clearance.Sepranolone IND filing
- 3mo agoRLMDRelmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business OfficerGlobeNewswireBrings nearly three decades of leadership spanning NMIBC, corporate strategy and business development to help advance NDV-01 and support the Company's long-term growth and value creation. CORAL GABLES, Fla., July
- 3mo agoRLMDRelmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026GlobeNewswireCORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
- 4mo agoRLMDRelmada Therapeutics Joins Russell 2000® and Russell 3000® IndexesGlobeNewswireCORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for
- 5mo agoRLMDRelmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone ProgramGlobeNewswireDr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada's sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES,
- 5mo agoRLMDRelmada Therapeutics to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireCORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central
- 6mo agoRLMDRelmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePositive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at
- 6mo agoRLMDRelmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026GlobeNewswireCORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and central
- 6mo agoRLMDRelmada Therapeutics to Present NDV-01 Abstracts at AUA2026GlobeNewswire12-Month Phase 2 data in High-Risk NMIBC to be presented Friday, May 15, 2026Phase 3 overview to be presented at Trials-in-Progress session on Sunday, May 17, 2026The Phase 3 "RESCUE" registrational program remains on
- 8mo agoRLMDRelmada Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswireCORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and
- 8mo agoRLMDRelmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement FinancingGlobeNewswireCORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and
- 8mo agoRLMDRelmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder CancerGlobeNewswireDurable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains
- 8mo agoHELPCMPSRLMDANRO+1Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersPR NewswireUSA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that ...
- 10mo agoRLMDRelmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate IndicationsGlobeNewswireFDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant
- 11mo agoRLMDRelmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic OncologyGlobeNewswirePoster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release
- 12mo agoRLMDRelmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate UpdatesGlobeNewswirePositive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3
- 1y agoRLMDRelmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025GlobeNewswireCORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and
- 1y agoRLMDRelmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireCORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and
- 1y agoRLMDRelmada Announces FDA Feedback Supporting 2 Separate Acceptable Registrational Study Paths for NDV-01 in Non-muscle Invasive Bladder CancerGlobeNewswireAnnounces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized
- 1y agoRLMDRelmada Therapeutics Appoints Distinguished Urologic Oncologist, Max Kates, MD, to the Clinical Advisory Board to Support Development of NDV-01GlobeNewswireDr. Kates' experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the NDV-01 Phase 3 program Phase 3 program for NDV-01 expected to begin in H1 2026
- 1y agoRLMDRelmada Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireCORAL GABLES, Fla., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology-related
- 1y agoRLMDRelmada Issues Mid-Year CEO Letter to ShareholdersGlobeNewswireCORAL GABLES, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology-related
- 1y agoRLMDRelmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoRLMDRelmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBCGlobeNewswire6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at
- 1y agoRLMDRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025GlobeNewswireCORAL GABLES, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada" or the "Company")), a clinical-stage biotechnology company advancing innovative therapies for oncology and
- 1y agoRLMDRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01GlobeNewswireDr. Lotan's distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada's NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES, Fla.,
- 1y agoRLMDRelmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-UrologyGlobeNewswireDr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 CORAL GABLES,
- 1y agoRLMDRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePositive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01
- 1y agoRLMDRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025GlobeNewswireCORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough
- 1y agoRLMDRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025GlobeNewswire90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release "GEM/DOCE" formulation* NDV-01 showed promising clinical activity
- 1y agoRLMDUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025GlobeNewswireCORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the
- 1y agoRLMDRelmada Therapeutics to Host KOL Event on Phase 2 NDV-01 DataGlobeNewswireApril 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES, Fla., April 24,
- 1y agoRLMDUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025GlobeNewswireCORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the
- 1y agoRLMDRelmada Therapeutics To Present NDV-01 Data at AUA2025GlobeNewswireCORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a clinical-stage biotechnology company, today announced the presentation of an abstract at the
- 1y agoRLMDRelmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateGlobeNewswireExpect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette
- 1y agoRLMDRelmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025GlobeNewswireCORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough
- 1y agoRLMDRelmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.GlobeNewswireNDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62,000
- 1y agoRLMDRelmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma ABGlobeNewswireRelmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement in Tourette
- 1y agoRLMDRelmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017GlobeNewswireCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),
- 1y agoRLMDRelmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceGlobeNewswireThe DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relmada is well
- 1y agoRLMDKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Relmada Therapeutics, Inc. (NASDAQ:RLMD) breached their
- 1y agoRLMDRelmada Therapeutics to Present at Jefferies London Healthcare ConferenceGlobeNewswireCORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", "the Company")), a late-stage biotechnology company addressing diseases of the central nervous system (CNS),
- 1y agoRLMDRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic DiseaseGlobeNewswireREL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase
- 2y agoRLMDRelmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRLMDRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatePR NewswireRelmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous...
- 2y agoRLMDRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswirePre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease